Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003380 · ClinicalTrials.gov registry record · Phase 1
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
A Phase 1 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00003380: Clinical Trial Phase 1 study, sponsored by Gynecologic Oncology Group.
NCT00003380 is a Phase 1 study that was terminated before completion, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003380, a Phase 1 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of liposomal doxorubicin and etoposide in treating patients who have recurrent or persistent ovarian, fallopian tube, or peritoneal cancer.
Interventions
- DRUG etoposide
- DRUG pegylated liposomal doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-05 |
| Phase | Phase 1 |
Why NCT00003380 stopped before completion
NCT00003380 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which etoposide is the first listed.
NCT00003380 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003380 about?
NCT00003380 is a clinical study titled "Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of liposomal doxorubicin and etopo...
What is the current status of trial NCT00003380?
This trial is currently terminated. It is a Phase 1 study. The study started on 1998-05.
What interventions are being tested in trial NCT00003380?
The interventions under investigation include: etoposide (DRUG), pegylated liposomal doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003380?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia